The efficacy and safety of anti-NKG2A (monalizumab) and anti-KIR (lirilumab) mAbs have been demonstrated in various clinical trials (38–41), and they have shown promising results against hematological malignancies. The gene discussed is KLRC1; the disease is hematologic disorder.